Literature DB >> 8538712

Acellular pertussis vaccines for infants.

K M Edwards, M D Decker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8538712     DOI: 10.1056/NEJM199602083340609

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Acellular pertussis vaccines have arrived.

Authors:  S A Halperin
Journal:  Can J Infect Dis       Date:  1996-11

Review 3.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

Review 4.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

Review 5.  An overview of the status of acellular pertussis vaccines in practice.

Authors:  A L Lopez; D A Blumberg
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 6.  Licensed pertussis vaccines in the United States. History and current state.

Authors:  Nicola P Klein
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

7.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 8.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 9.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.

Authors:  Nathalie Mielcarek; Anne-Sophie Debrie; Severine Mahieux; Camille Locht
Journal:  Clin Vaccine Immunol       Date:  2010-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.